Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants

Current SARS-CoV-2 vaccines provide protection for COVID-19-associated hospitalization and death, but remain inefficient at inhibiting initial infection and transmission. Despite updated booster formulations, breakthrough infections and reinfections from emerging SARS-CoV-2 variants are common. Intr...

Descrición completa

Detalles Bibliográficos

Principais autores:	Michael J. Moser, Lindsay Hill-Batorski, Richard A. Bowen, Sarah M. Matejka, David Marshall, Yoshihiro Kawaoka, Gabriele Neumann, Pamuk Bilsel
Formato:	Artigo
Idioma:	Inglês
Publicado:	MDPI AG 2023-06-01
Series:	Vaccines
Assuntos:	influenza SARS-CoV-2 COVID-19 vaccine intranasal mucosal
Acceso en liña:	https://www.mdpi.com/2076-393X/11/6/1063
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!